A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 565-573

  Perng, Reury Perng ^a,b   Wu, Ming Fang ^a,b   Lin, Shan Yang ^b   Chen, Yuh Min ^a,b   Lin, Jye Yee ^c   Whang Peng, Jacqueline ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Intrapleural paclitaxel; Malignant pleural effusions; Pharmacokinetics

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; PACLITAXEL; PLEURAL EFFUSION, MALIGNANT; TREATMENT OUTCOME; VOMITING;

EID: 0030772757     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00003     Document Type: Article

References (36)

1. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63: 695-702.
2. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388-94.
3. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-8.
4. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.
5. Reichman BS, Seidman AD, Crown JP, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51.
6. Rowinsky EK, Cazenave LA, Donehower RC. Paclitaxel: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-59.
7. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986; 13: 219-42.
8. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10: 1485-91.
9. Monsarrat B, Mariel E, Cros S, et al. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Dispos 1990; 18: 895-901.
10. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093-100.
11. O'Moore PV, Mueller PR, Simeone JF, et al. Sonographic guidance in diagnostic and therapeutic interventions in the pleural space. Am J Roentgenol 1987; 149: 1-5.
12. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
14. Ruckdeschel JC, Moores D, Lee JY, et al. Intrapleural therapy for malignant pleural effusions: a randomized comparison of bleomycin and tetracycline. Chest 1991; 100: 1528-35.
15. Anderson GB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer 1974; 33: 916-22.
16. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120: 56-64.
17. Heffner JE, Unruh LC. Tetracycline pleurodesis. Adios, farewell, adieu (editorial). Chest 1992; 101, 5-7.
18. Hatta T, Tsubota N, Yoshimura M, Yanagawa M. Intrapleural minocycline for postoperative air leakage and control of malignant pleural effusion. Kyobu Geka 1990; 43: 283-6.
19. Kitamura S, Sugiyama Y, Izumi T, Haysdh R, Kosaka K. Intrapleural doxycycline for control of malignant pleural effusion. Curr Ther Res 1981; 30: 515-21.
20. Mansson T. Treatment of malignant pleural effusion with doxycycline. Scand J Infect Dis 1988; 53 (suppl): 29-34.
21. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg 1993; 55: 1115-21.
22. Fentiman IS, Rubens RD, Hayward JL. A comparison of intracavitary talc and tetracycline for the control effusions secondary to breast cancer. Eur J Cancer Clin Oncol 1986; 22: 1079-81.
23. Hamed H, Fentiman IS, Chaudary MA, Rubens RD. Comparison of intercavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg 1989; 76: 1266-7.
24. Webb WR, Ozmen V, Moulder PV, Shabahang B, Breaux J. Iodized talc pleurodesis for the treatment of pleural effusions. J Thorac Cardiovasc Surg 1992; 103: 881-5.
25. Walsh FW, Alberts M, Soloman DA, Goldman AL. Malignant pleural effusions: pleurodesis using a small-bore percutaneous catheter. South Med J 1989; 82: 963-65, 72.
26. Morrison MC, Mueller PR, Lee MJ, et al. Sclerotherapy of malignant pleural effusion through sonographically placed small-bore catheters. Am J Roentgenol 1992; 158: 41-3.
27. Landreneau RJ, Mack MJ, Hazelrigg SR, Naunheim KS, Keenan RJ, Ferson PF. The role of video-assisted thoracic surgery in thoracic oncological practice. Cancer Invest 1995; 13: 526-39.
28. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985; 12: 54-75.
29. Yamaguchi E, Nagai A, Sakamoto K, Takizawa T. Morphological changes in the pleura caused by intracavitary administration of bleomycin. Gan To Kagaku Ryoho 1991; 18: 971-5.
30. Vargas FS, Wang NS, Lee HM, Gruer SE, Sasson CSH, Light RW Effectiveness of bleomycin in comparison to tetracycline as pleural sclerosing agent in rabbits. Chest 1993; 104: 1582-4.
31. Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990; 26: 755-62.
32. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241-8.
33. Spriggs AI, Boddington MM, eds. The cytology of effusions, 2 edn. London: William Heinemann 1968: 21-3.
34. Sahn SA, Good JT, Jr. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med 1988; 108: 345-9.
35. Rodriguez-Panadero F, Mejias JL. Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989; 139: 663-7.
36. Good JT, Jr. Taryle DA, Sahn SA. The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 1985, 737-41.